Oramed Pharmaceuticals
ORMP
35 hedge funds and large institutions have $4.73M invested in Oramed Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
141% more capital invested
Capital invested by funds: $1.97M → $4.73M (+$2.76M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
74% more call options, than puts
Call options by funds: $584K | Put options by funds: $335K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
13% more funds holding
Funds holding: 31 → 35 (+4)
3.03% more ownership
Funds ownership: 2.77% → 5.8% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$1.28M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$612K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$305K |
| 4 |
Renaissance Technologies
New York
|
+$120K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
ICM Asset Management
Spokane,
Washington
|
-$119K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$97.7K |
| 3 |
Millennium Management
New York
|
-$40K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$20.5K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$20K |
ORMP Hedge Fund Activity: Q2 2020 in Review
35 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2020, worth a combined $4.73M — up 141% from $1.97M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ORMP positions and 5 closed out — a net gain of 4 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Jess S. Morgan & Co, adding an estimated $1.28M. The largest seller was ICM Asset Management, exiting entirely with an estimated $119K sold.
- 35 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2020, up from 31 in Q1 2020.
- Funds reported $4.73M of Oramed Pharmaceuticals stock for Q2 2020, up 141% quarter-over-quarter.
- 9 funds opened new Oramed Pharmaceuticals positions in Q2 2020 and 5 closed out, a net change of +4 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2020 was Jess S. Morgan & Co, an estimated $1.28M added.
- The largest Oramed Pharmaceuticals seller in Q2 2020 was ICM Asset Management, an estimated $119K sold.
Based on aggregated 13F filings for Q2 2020.